Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 29, 2021

AB Science to begin second Phase II Covid-19 clinical trial with masitinib

Study AB21002 will focus on masitinib’s antiviral activity against the virus to treat patients at an early stage of the disease.

AB Science has secured approval from the Regulatory Authorities of Russia and South Africa to commence Study AB21002, a second Phase II Covid-19 clinical trial with masitinib.

Masitinib is an orally administered tyrosine kinase inhibitor, which is being developed as a novel SARS-CoV-2 protease inhibitor antiviral therapy.

The company claims that it is currently one of the most advanced oral protease inhibitor antiviral drugs which are in clinical development.

Study AB21002 is a randomised, double-blind, placebo-controlled Phase II clinical trial that will be performed in patients with symptomatic mild to moderate Covid-19 to evaluate the efficacy of masitinib.

It will directly focus on masitinib’s antiviral activity against the SARS-CoV-2 virus to treat patients at an early stage of the disease.

The antiviral efficacy of the drug will be evaluated at three different dosages, administered as an add-on to best supportive care, with respect to placebo plus best supportive care.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Study AB21002 will enrol 78 patients aged 18 years and above at medical centres in France and other countries.

It will also target non-hospitalised patients with mild disease or hospitalised Covid-19 patients without resorting to non-invasive ventilation.

The trial’s primary efficacy objective will be to demonstrate that the drug can reduce the SARS-CoV-2 viral load faster compared to a placebo control group, which will be given best supportive care.

University of Chicago Pritzker School for Molecular Engineering professor Savas Tay said: “In a context where we face the emergence of a number of SARS-CoV-2 variants of concern, the development of efficacious antiviral therapeutics is urgently needed.

“Because masitinib specifically targets the catalytic residues of 3CLpro, its antiviral activity is likely to be insensitive to genetic alterations of the Spike protein.

“Thus, masitinib constitutes a uniquely valuable therapeutic option for both ancestral SARS-CoV-2 and variants against which vaccines or monoclonal antibodies may become less or not effective.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU